A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma (NCT06023589)
A Multicentre, Randomised, Double-Blind, Parallel-Group Placebo-Controlled, Phase 3, Efficacy and Safety Study of Tezepelumab in 5 to < 12 Year Old Children With Severe Uncontrolled Asthma (HORIZON)
🩺 Plain-English Summary (8th-Grade Level)
To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled corticosteroids (ICS) and at least one additional asthma controller medication with or without oral corticosteroids.
Who can join: Review the eligibility criteria below.
Location: Research Site — Montgomery, Alabama
Age range: 5 Years to 11 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (147 Sites)
Showing the first 25 of 147 sites.
- Research Site — Montgomery, Alabama
- Research Site — Phoenix, Arizona
- Research Site — Little Rock, Arkansas
- Research Site — La Jolla, California
- Research Site — Long Beach, California
- Research Site — Orange, California
- Research Site — San Diego, California
- Research Site — Atlanta, Georgia
- Research Site — Savannah, Georgia
- Research Site — Baltimore, Maryland
- Research Site — Boston, Massachusetts
- Research Site — Boston, Massachusetts
- Research Site — Ann Arbor, Michigan
- Research Site — Detroit, Michigan
- Research Site — Northfield, New Jersey
- Research Site — Hawthorne, New York
- Research Site — Schenectady, New York
- Research Site — Staten Island, New York
- Research Site — Chapel Hill, North Carolina
- Research Site — Cincinnati, Ohio
- Research Site — Cleveland, Ohio
- Research Site — Toledo, Ohio
- Research Site — Oklahoma City, Oklahoma
- Research Site — Columbia, South Carolina
- Research Site — Coppell, Texas
📞 Contact the Study Coordinator
Phone: (877) 240-9479
Email: information.center@astrazeneca.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Asthma
- Investigating Dupilumab's Effect in Asthma by Genotype — Boston, Massachusetts
- Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma — Bakersfield, California
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma — Saraland, Alabama
- Reduce IDentified UNcontrolled Asthma — San Diego, California
- A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma — Little Rock, Arkansas
- REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study — La Jolla, California
Explore by condition: All Asthma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.